[A21-151] Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2022
Project no.:
A21-151
Commission:
Commission awarded on 30.11.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Add-on therapy for patients from 6 years and above with relapsing remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-150 | Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-58 | Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-03 | Mepolizumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-152 | Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-43 | Mepolizumab (eosinophilic granulomatosis with polyangiitis) – Addendum to Commission A21-151 | Commission completed |
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.